Glycotope Biotechnology expands cleanroom facilities

Published: 5-Apr-2011
Design & Build Ingredients

GMP production capacity will increase to 11kg of antibody a year


Heidelberg-based Glycotope Biotechnology, a full subsidiary of Germany company Glycotope GmbH, has initiated the setup of further cleanroom facilities as a first step in the expansion of its GMP-production capacities.

By mid 2011, the company will be able to produce 4kg of recombinant antibodies per year and up to 11 kg upon completion of works towards the end of 2011. In total an additional 1400m2 of facility and office space will be created.

“In particular the expansion of our DSP (downstream processing) capacities now places us among the top providers of GMP-production for recombinant proteins and in particular antibodies in Germany,” said Dr Steffen Goletz, founder and ceo of Glycotope GmbH.

  • Companies:
  • Glycotope GmbH
See more

You may also like

Ingredients

Therapeutic: acoramidis for transthyretin amyloid cardiomyopathy

Read more
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare progressive disease that results from genetic mutations or ageing; misfolded TTR protein accumulates as amyloid fibrils in the myocardium

Trending Articles

  1. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production
  2. Rousselot announces access to pure gelatins through BIO INX Research and technical grade gelatins are now available for online purchase in Canada, Europe, South Korea and the US
  3. Olon: celebrating 10 years of daptomycin and doubled production capacity Olon's Daptomycin celebrates its 10th anniversary, and in the very year that marks the first decade of production of this first in a new class of antibiotics that represented a breakthrough in the treatment of skin infections, the leading API supplier group announces the doubling of its production to meet and exceed global demand for the active ingredient
  4. Biocatalysis versus chemocatalysis Dr Cynthia A. Challener, Scientific Content Editor, Nice Insight, compares the benefits of various catalytic technologies and concludes that the outright winner is the patient
  5. AbbVie and Eisai obtain additional approval for Humira The monoclonal antibody, Humira, is used in the treatment of patients who have had an inadequate response to conventional therapy for pustular psoriasis

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Ingredients

Therapeutic: acoramidis for transthyretin amyloid cardiomyopathy

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare progressive disease that results from genetic mutations or ageing; misfolded TTR protein accumulates as amyloid fibrils in the myocardium
Ingredients

Therapeutic: lutikizumab for hidradenitis suppurativa

Hidradenitis suppurativa (HS) — also known as acne inversa — is a chronic, recurrent and progressive inflammatory disease that leads to irreversible skin damage and disability
Ingredients

Olon: celebrating 10 years of daptomycin and doubled production capacity

Olon's Daptomycin celebrates its 10th anniversary, and in the very year that marks the first decade of production of this first in a new class of antibiotics that represented a breakthrough in the treatment of skin infections, the leading API supplier group announces the doubling of its production to meet and exceed global demand for the active ingredient
Ingredients

Rousselot announces access to pure gelatins through BIO INX

Research and technical grade gelatins are now available for online purchase in Canada, Europe, South Korea and the US
Manufacturing

Exploring TiO2-free hard capsules

The quest for TiO2 alternatives underscores the unwavering commitment of the pharmaceutical industry to deliver safe and effective medicines to patients worldwide
Ingredients

C2 PHARMA announces upcoming launch of new oxybuprocaine hydrochloride API

C2 PHARMA excited to announce the upcoming launch of its new API, oxybuprocaine HCL, an ingredient that will be manufactured by manufacturing partner Laurus Labs
Design & Build

CordenPharma expands early clinical peptide manufacturing offering

CordenPharma is pleased to announce the commissioning of new GMP capacities at Frankfurt to manufacture early clinical phase peptide APIs for pharma and biotech customers
Subscribe now